Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant QL1706 plus paclitaxel (albumin-bound) and cisplatin in locally advanced cervical cancer
ChiCTR2500107835Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in Cervical Cancer (CC), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Pathological complete response (pCR). Planned start Aug 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2500107835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107835.